Double Bond Pharmaceutical International Past Earnings Performance
Past criteria checks 0/6
Double Bond Pharmaceutical International's earnings have been declining at an average annual rate of -7.5%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been declining at an average rate of 14.7% per year.
Key information
-7.5%
Earnings growth rate
19.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 30.5% |
| Revenue growth rate | -14.7% |
| Return on equity | -323.8% |
| Net Margin | -1,265.2% |
| Next Earnings Update | 24 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Double Bond Pharmaceutical International makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1 | -17 | 10 | 0 |
| 30 Sep 23 | 1 | -16 | 10 | 0 |
| 30 Jun 23 | 1 | -17 | 10 | 0 |
| 31 Mar 23 | 1 | -15 | 8 | 0 |
| 31 Dec 22 | 1 | -15 | 8 | 0 |
| 30 Sep 22 | 1 | -3 | 7 | 0 |
| 30 Jun 22 | 1 | -5 | 7 | 0 |
| 31 Mar 22 | 1 | -8 | 8 | 0 |
| 31 Dec 21 | 1 | -9 | 9 | 0 |
| 30 Sep 21 | 1 | -21 | 8 | 0 |
| 30 Jun 21 | 0 | -22 | 8 | 0 |
| 31 Mar 21 | 1 | -19 | 8 | 0 |
| 31 Dec 20 | 1 | -18 | 8 | 0 |
| 30 Sep 20 | 4 | -13 | 8 | 0 |
| 30 Jun 20 | 4 | -11 | 8 | 0 |
| 31 Mar 20 | 5 | -10 | 8 | 0 |
| 31 Dec 19 | 4 | -8 | 8 | 0 |
| 30 Sep 19 | 2 | -9 | 9 | 0 |
| 30 Jun 19 | 1 | -9 | 8 | 0 |
| 31 Mar 19 | 1 | -10 | 8 | 0 |
| 31 Dec 18 | 1 | -11 | 8 | 0 |
| 30 Sep 18 | 0 | -12 | 8 | 0 |
| 30 Jun 18 | 0 | -13 | 8 | 0 |
| 31 Mar 18 | 1 | -13 | 9 | 0 |
| 31 Dec 17 | 1 | -13 | 9 | 0 |
| 30 Sep 17 | 1 | -12 | 8 | 0 |
| 30 Jun 17 | 1 | -11 | 8 | 0 |
| 31 Mar 17 | 0 | -10 | 7 | 0 |
| 31 Dec 16 | 0 | -8 | 6 | 0 |
| 30 Sep 16 | 0 | -8 | 6 | 0 |
| 30 Jun 16 | 0 | -7 | 6 | 0 |
| 31 Mar 16 | 0 | -5 | 5 | 0 |
| 31 Dec 15 | 0 | -4 | 4 | 0 |
Quality Earnings: DBP B is currently unprofitable.
Growing Profit Margin: DBP B is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DBP B is unprofitable, and losses have increased over the past 5 years at a rate of 7.5% per year.
Accelerating Growth: Unable to compare DBP B's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DBP B is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (3.5%).
Return on Equity
High ROE: DBP B has a negative Return on Equity (-323.76%), as it is currently unprofitable.